<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892369</url>
  </required_header>
  <id_info>
    <org_study_id>H-18063495</org_study_id>
    <nct_id>NCT03892369</nct_id>
  </id_info>
  <brief_title>FGF21 and Its Role in Alcohol Dependence</brief_title>
  <official_title>Physiological Effects of FGF21 in Humans and Its Pathophysiological Role in Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plasma fibroblast growthfactor-21 (FGF21) responses to acute alcohol exposure will be
      evaluated in three groups: A: 15 individuals diagnosed with alcohol dependence (ICD10 code
      F10.2) and no alcoholic liver diseases, B: 15 healthy individuals with one or two parents
      with alcohol dependence, and C: 15 healthy matched controls without history of or disposition
      to alcohol dependence. The experimental day consists of a load of 0.5 g ethanol per kg body
      weight ingested from time 0-10 minutes followed by a 7 h period in which blood will be
      sampled with frequent intervals, rating of preference for ethanol, salt, sour, bitterly and
      sweets, sensations of hunger, appetite, satiety, headache, and nausea will be evaluated using
      visuel analogue scale and resting energy expenditure will be evaluated using indirect
      calorimetry.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Three matched groups. Group A: participants diagnosed with alcohol dependence, group B: participants with a father diagnosed with alcohol dependence, and C: a healthy control group.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibroblast growthfactor-21</measure>
    <time_frame>One year</time_frame>
    <description>Plasma FGF21 concentrations, a member of the endocrine FGF-family</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ethanol</measure>
    <time_frame>One year</time_frame>
    <description>Plasma ethanol concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>One year</time_frame>
    <description>Plasma glucose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin and C-peptide</measure>
    <time_frame>One year</time_frame>
    <description>Serum insulin and C-peptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>One year</time_frame>
    <description>Plasma glucagon concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor-alpha (TNF)</measure>
    <time_frame>One year</time_frame>
    <description>Plasma TNF-alpha concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipopolysaccharide Binding Protein (LBP)</measure>
    <time_frame>One year</time_frame>
    <description>Plasma LBP concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma (INF)</measure>
    <time_frame>One year</time_frame>
    <description>Plasma INF-gamma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukine-10 (IL-10)</measure>
    <time_frame>One year</time_frame>
    <description>Plasma IL-10 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukine-8 (IL-8)</measure>
    <time_frame>One year</time_frame>
    <description>Plasma IL-8 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukine-6 (IL-6)</measure>
    <time_frame>One year</time_frame>
    <description>Plasma IL-6 concentrations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alcohol Abuse or Dependence</condition>
  <arm_group>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant receive 0.5 g ethanol per kg body weight over 10 minutes. Subsequently blood samples are taken frequently the next ten hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Ethanol administration</description>
    <arm_group_label>Alcohol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Caucasian males between 25 and 65 years of age

          -  BMI between 19 and 27 kg/m2

          -  Normal haemoglobin

          -  Normal fasting plasma glucose concentration (&lt; 6 mmol/l) and normal glycated
             haemoglobin A1c (HbA1c) (&lt; 42 mmol/mol)

        Participants with a father diagnosed with alcohol dependence (group B):

          -  Father diagnosed with alcohol dependence

          -  Weekly alcohol intake of less than 14 units of alcohol (of 12 g)

          -  Normal Alcohol Use Disorders Identification Test (AUDIT) score

        Healthy participants (group C):

          -  Weekly alcohol intake of less than 14 units of alcohol (of 12 g)

          -  Normal AUDIT score

        Exclusion Criteria:

          -  Liver disease evaluated by plasma alanine aminotransferase (ALAT) &gt; 3 Ã— normal level,
             an international normalised ratio (INR) below normal values, or biopsy-verified
             alcoholic liver disease

          -  Diabetes mellitus

          -  Anaemia

          -  Nephropathy

          -  Other diseases the investigator finds disruptive for participation in the study.

        Participants with a father diagnosed with alcohol dependence (group B):

        - Former alcohol dependence or abuse

        Healthy participants (group C):

          -  First-degree relatives with diabetes, liver disease and/or alcohol dependence

          -  Former alcohol dependence
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amalie R Lanng, MD</last_name>
    <phone>+4521649983</phone>
    <email>amalie.rasmussen.lanng@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amalie R Lanng, MD</last_name>
      <phone>38674434</phone>
      <email>amalie.rasmussen.lanng@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Head of Clinical Metabolic Physiology, Principal Investigator, Clinical Professor, PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>FGF21</keyword>
  <keyword>Alcohol dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

